Bingham Vaccine Deal for ClearPath
Bingham partner Carl Valenstein and counsel Kelly Grez represented ClearPath Development Company in a strategic partnership with Astellas Pharma Inc. to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership, established to support Astellas’ goal of building a global vaccine franchise, launched its first company, RSV Corporation, in December 2013.